The underlying mechanism for the requirement of HoxA9 expressing character of MSCs in the treatment of ALI/ARDS may be partly related to the promoted proliferation and inhibitory inflammatory adhesion. Here, HOXA9 is linked to acute respiratory distress syndrome.